Company Interview / Partnering to diversify brain health revenue streams

Brad O'Connor CEO of Cogstate (ASX: CGS) expands on the company's growth trajectory. He sees value in partnering with other companies working in clinical trials. Cogstate is also strategically diversifying into central nervous system diseases, beyond Cogstate's original focus on Alzheimer's disease.

O'Connor explains Cogstate's competitive edge in employing proprietary digital assessments sensitive to brain health changes. Unlike broader competitors, O'Connor says Cogstate's niche facilitates partnerships, opening doors to various future opportunities. Key shareholders like the Myer and Dolby families, alongside Australian Ethical Investments (ASX: AEF) are expected to continue their long-term support for the company.

Listen for Brad's take on how Cogstate is positioned to partner with large pharma companies to accelerate growth.*The information contained in this event is general in nature and is not intended as advice.

Before acting on information you've seen or heard at this event, you should seek professional financial advice which takes into account your personal circumstances.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD